EHA 2022 preview – some good news at last
Positive data result in positive share price movements – something of a novelty in the current market.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Market crash throws up a rich deal for Cullinan
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
Six months on, Biohaven succumbs to Pfizer
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.
Arcus sets the hopes for Tigit in lung cancer
As biopharma awaits Roche’s pivotal Skyscraper-01 data Arcus gives its investors some more tea leaves to read.
